Umar Khan
@DrKhanUmar
Followers
90
Following
1K
Media
52
Statuses
738
MBBS, FRACP, FAANMS - Nuclear Medicine and General & Acute Medicine Physician
Melbourne, Victoria
Joined September 2020
A clinical trial co-led by Peter Mac has shown a way to reduce the need for invasive biopsies to check for prostate cancer. It found PSMA PET/CT scanning could halve the number of people requiring a biopsy, without missing any harmful cancers. More: https://t.co/MXB3n39KC5
0
8
13
Clinical correlation no longer required: An LLM practical use scenario in PET reporting. https://t.co/SSYiTrxPvn
#NuclearMedicine #PETscan #AI @DrMHofman
jnm.snmjournals.org
TO THE EDITOR: Incidental findings from PET are common, induce unnecessary patient anxiety, and incur substantial costs to the health care system, with further diagnostic clarification potentially...
0
3
6
PET-guided, biologically individualized radiotherapy has the potential to shift the success rate of head and neck cancer treatment at five years from approximately 60% to 90%. https://t.co/tN5967vfdy
#NuclearMedicine #HNSCC @MartaLazzeroni @Stockholm_Uni
0
4
7
Early quantitative ⁹⁹mTc-PYP SPECT/CT imaging can reliably differentiate ATTR-CM from non–ATTR-CM cases, reducing the need for a prolonged uptake period, streamlining clinical workflows, and more. https://t.co/2xz6APpDkh
#NuclearMedicine @DorbalaSharmila
0
2
5
Terbium-161 vs lutetium-177: Comparing next-gen radioligands for #ProstateCancer. @DrMHofman @PeterMacCC joins Oliver Sartor, MD @EJHospital to discuss the #VIOLET study evaluating Terbium-161 PSMA therapy in #mCRPC. #WatchNow > https://t.co/xG6uE2HGW6
0
4
7
0
1
2
Multicenter, IAEA-supported trial confirms that ⁶⁸Ga-PSMA-11 PET/CT is superior to MRI for primary staging of high-risk #ProstateCancer and can benefit patients from countries of all income levels. https://t.co/poMLJN3sM0
#NuclearMedicine #PETscan
1
7
18
Lutetium-177 outperforms cabazitaxel in #mCRPC: Real-world Flatiron database analysis. @ziremozay @huntsmancancer joins @neerajaiims discussing a comparative effectiveness study of lutetium-177 vs cabazitaxel in metastatic castration-resistant #ProstateCancer. #WatchNow >
0
4
7
⁶⁸Ga-PSMA-11 PET tumor volume predicts overall survival of patients with metastatic prostate cancer undergoing taxane-based chemotherapy. https://t.co/xuYWnBMZS6
#NuclearMedicine #MolecularImaging #ProstateCancer @DrAGafita @MatthiasEiber @liljasolnes
0
5
12
Personalized intensification of treatment for hormone-sensitive prostate cancer @NatRevClinOncol Goal: hit cancer harder, earlier & smarter with biology, risk & PSMA-PET. ADT+ARPI = backbone for most pts. Docetaxel for de novo high-volume. Prostate RT: survival boost in
4
33
89
🎯🎯.- How to apply the current evidence in the treatment of mCSPC!! Excellent review.🙌 https://t.co/CWNtJkMAZM 👉.- The new molecular precision "triplet intensification" is here. 👉.- A HRR (BRCA2+) alt and pTEN loss population have a poor prognosis. 👉.- We need to better
7
66
130
First in the world @GEHealthCare Omni 128cm Total Body PET just installed at @PeterMacCC ... serial number 001. 50 times the sensitivity of our existing PET scanner enabling faster scanning with less radiation and greater clarity. Our new centre seamlessly integrates
A major step forward for precision medicine today. Peter Mac has installed cutting-edge @GEHealthCare total body PET/CT technology — supported by $15M in new grants and funding.
1
6
44
Biochemical responses to rechallenge and extended ¹⁷⁷Lu-PSMA therapy are promising, with at least 50% reductions in PSA levels observed in a significant proportion of highly selected patients. https://t.co/eRmJi12kV9
#NuclearMedicine #RPTherapy @MatthiasEiber
1
1
11
High tracer accumulation in 70% of patients with untreated hepatocellular carcinoma suggests a possible use for PSMA-directed radiopharmaceutical therapy in an end-stage setting. https://t.co/O4FeNwIQoe
#NuclearMedicine #HCC #RPTherapy
0
4
11
PSMA PET staging is decreasing the use of surgical local therapy and increasing systemic therapy use in the Veterans Affairs system. https://t.co/1mCWUXnCFL
#NuclearMedicine #PETscan #ProstateCancer @stensy @megan_caram
0
4
16
1/ 🚨 Pleased to share that our latest manuscript is out now in @EUplatinum! Baseline and on-treatment #ctDNA biomarkers in men with advanced #ProstateCancer treated with #LuPSMA. https://t.co/koAm8SgnK9 Thanks to @LouiseKostos Heidi Fettke @PeterMacCC
5
28
73
The dx & tx of ICI myocarditis in #cardioonc is always humbling given its myriad, challenging presentations. ...but 🥸 as a #brugada phenocopy? @DOM_UCLA @AlexTalishinsky @UCLAHealthJCCC & our #Epeeps report/🔎this mysterious case in #JACCCaseReports! https://t.co/5RWz5QcSHX
3
18
55
Current Issue: Incidental Detection of Brain Metastases From a Pulmonary Large Cell Neuroendocrine Carcinoma at 18F-Fluorocholine PET/CT in a Context of Primary Hyperparathyroidism https://t.co/yTfVBAAye2
0
6
14
Current Issue: Extensive Pulmonary AL Amyloidosis Mimicking Miliary Tuberculosis: The Diagnostic Utility of: 99m: Tc-PYP Scintigraphy https://t.co/rTZ8IA4Mni
0
6
15
The PUMA framework provides a practical solution for integrating and aligning multiple PET tracer images into a single composite view. https://t.co/txGSPpPLjY
#NuclearMedicine #PETscan @lalith_shiyam @SimonRCherry @rdbadawi
0
2
1